The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Cisplatin resistance and opportunities for precision medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., & Deeley, R. G. (1994) · PubMed · Cited by 770
Watson, M. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.275 · Cited by 668
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
Cited by
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Ferroptosis: A Novel Anti-tumor Action for Cisplatin
Guo, J., Xu, B., Han, Q., Zhou, H., Xia, Y., Gong, C., Dai, X., Li, Z., & Wu, G. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2016.572 · Cited by 777
Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs
Su, Y., Zhao, B., Zhou, L., Zhang, Z., Shen, Y., Lv, H., AlQudsy, L. H. H., & Shang, P. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.015 · Cited by 576
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical and Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 366
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Weng, Q., Sun, H., Fang, C., Xia, F., Liao, H., Lee, J., Wang, J., Xie, A., Ren, J., Guo, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21714-2 · Cited by 302
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
Lelièvre, P., Sancey, L., Coll, J.-L., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123594 · Cited by 271
Iyer, J. G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.815 · Cited by 260
Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy
Liu, P., Hao, L., Liu, M., & Hu, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1161472 · Cited by 58
Jin, X., Gong, L., Peng, Y., Li, L., & Liu, G. (2021) · Aging · doi:10.18632/aging.202137 · Cited by 24
“However, cisplatin treatment has been well documented to cause drug resistance [18].”
Background
Metadata
- Authors
- Amable, L.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 106
- Pages
- 27-36
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2274595380
- Cited by
- 589
- References
- 99
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.